facebook button NKTR-214 and Nivolumab in Previously Untreated Renal Cell Carcinoma
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

NKTR-214 and Nivolumab in Previously Untreated Renal Cell Carcinoma

Sponsor: Nektar Therapeutics

Protocol 17-214-09. A study of NKTR-214 plus nivolumab in patients with advanced or metastatic renal cell carcinoma that has not received prior treatment. Patients will be randomized to receive either NKTR-214 plus nivolumab or investigator's choice of sunitinib or cabozantinib.